InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-9.1%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by WELCH DANIEL G, Director. Director active across 4 companies, notably Seagen Inc.. In total, 19 reports have been logged. Activity tracked since 14 May 2021. The latest transaction was disclosed on 15 May 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations19 total
5,740 shares0Common StockSEC:0000950170-25-074667:0
5,345 shares0Common StockSEC:0000950170-24-075488:0
293,203 shares@ US$1.74100.0% of flowClass A Common StockSEC:0001415889-24-014769:0
4,750 shares@ US$229.0048.1% of flowCommon StockSEC:0000950170-23-070874:0
1,812 shares@ US$135.6310.9% of flowCommon StockSEC:0001203311-23-000087:0
3,860 shares0Common StockSEC:0001209191-23-035686:0
2,044 shares0Common StockSEC:0001203311-23-000057:0
1,864 shares@ US$135.6311.2% of flowCommon StockSEC:0001203311-23-000046:0
5,150 shares@ US$64.3814.5% of flowCommon StockSEC:0000899243-23-012178:0
995 shares@ US$38.821.7% of flowCommon StockSEC:0000899243-23-010823:0
2,037 shares@ US$38.823.5% of flowCommon StockSEC:0000899243-23-008886:0
5,758 shares@ US$38.8210.1% of flowCommon StockSEC:0000899243-23-008695:0
123,508 sharesOrdinary SharesSEC:0001209191-23-008168:0
3,300 shares0Common StockSEC:0001209191-22-039568:0
1,503 shares0Common StockSEC:0000899243-22-018459:0
2,145 shares0Common StockSEC:0001209191-21-043549
2,145 shares0Common StockSEC:0001209191-21-043549:0
1,402 shares0Common StockSEC:0001203311-21-000030:0
1,402 shares0Common StockSEC:0001203311-21-000030
19 of 19 declarations
About WELCH DANIEL G
Daniel G. Welch is a Director of Seagen Inc. and Ultragenyx Pharmaceutical Inc. In this role, he participates in the governance and strategy of these companies, bringing his expertise in the pharmaceutical sector.
